BioClinica Inc., a global provider of clinical trial management solutions, announced that TauRx Therapeutics has signed agreements with BioClinica to use Trident IWR/IVR and Imaging Core Lab (ICL) solutions to support its upcoming Phase 3 clinical trials. TauRx, a Singapore-based company, focuses its research on therapies and diagnostics for the treatment of Alzheimer's disease and other neurodegenerative disorders. With primary research facilities in Aberdeen in the United Kingdom, TauRx is the latest European customer to select BioClinica for both Imaging and eClinical offerings.
TauRx has selected Trident IWR/IVR for a series of expanded trials for its pipeline of neurology treatment candidates. “TauRx chose Trident IWR to reduce the lead time and effort needed to prepare for our studies, while supporting all of our randomization and clinical supplies tracking requirements,” said Dr. Jiri Hardlund, Chief Medical Officer for TauRx. “When we investigated the available technologies, it was clear that Trident offered clear advantages for our trials’ requirements.”
A separate selection team evaluated imaging solutions, and also selected BioClinica for its Imaging Core Lab solutions for processing MRI data. “MRI imaging represents a critical eligibility and safety component of our clinical studies,” said Dr. Diane Downie, Global Logistics and Support Lead at TauRx. “Our MRI imaging partner needed to understand the unique requirements of our pioneering scientific research. BioClinica’s MRI imaging solution best matched all of our requirements.”
BioClinica’s Imaging Core Lab uses innovative technology to efficiently acquire, process, and read medical images. With more than 22 years of world-wide experience, the team brings the scientific knowledge to make that technology work for sponsors of any size. With a highly-regarded medical affairs team and deep roster of collaborative consultants, BioClinica provides the imaging expertise necessary to ensure the highest quality clinical trial outcomes.
"BioClinica is clearly a technology leader for clinical trial applications,” said Peter Benton, BioClinica's eClinical Solutions President. “While great technology is essential, our business model also offers a fresh approach for clinical trial support -- one that makes it faster and more cost-efficient than other alternatives, whether the sponsor is large or small. Combined with our global reach, experience and customer support, we believe no other solution matches BioClinica for value or performance.”
Date: November 6, 2012
Source: BioClinica Inc.